NCT07105176View on ClinicalTrials.gov

HS-IT101 Injection for Advanced NSCLC

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2027

Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

Cyclophosphamide

Cyclophosphamide administered via intravenous infusion once daily for 3 consecutive days.

DRUG

Fludarabine

Fludarabine is administered once daily via intravenous infusion for 4 consecutive days.

DRUG

IL-2 (interleukin 2)

IL-2 administered subcutaneously once daily. Dosing may be adjusted based on subject tolerance, including modifications to dose quantity, administration frequency, or complete treatment discontinuation, with a maximum treatment duration of 3 days.

DRUG

HS-IT101 monotherapy

TIL Injection administered by intravenous infusion over 30-60 minutes.

Trial Locations (1)

Unknown

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors
lead

Qingdao Sino-Cell Biomedicine Co., Ltd.

INDUSTRY